Akaza Hideyuki
Strategic Investigation on Comprehensive Cancer Network, Interfaculty Initiative in Information Studies/Graduate School of Interdisciplinary Information Studies, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo, 153-8904, Japan.
Curr Urol Rep. 2016 Nov;17(11):84. doi: 10.1007/s11934-016-0636-9.
The clinical efficacy of combined therapy (CAB) has been clearly recognized by the results of the STRIVE trial. Although enzalutamide has shown a stronger effect on CRPC, bicultamide, a classical anti-androgen, has shown a significant effect. In addition, it can be deduced that CAB is a strong tool for hormone naïve advanced prostate cancer. Cost-effective evaluation for CAB with bicultamide or enzalutamide is warranted, especially for the resource-limited cohort.
STRIVE试验的结果已明确证实了联合疗法（CAB）的临床疗效。虽然恩杂鲁胺对去势抵抗性前列腺癌（CRPC）显示出更强的效果，但传统抗雄激素药物比卡鲁胺也显示出显著疗效。此外，可以推断CAB是初治晚期前列腺癌的有力治疗手段。对使用比卡鲁胺或恩杂鲁胺的CAB进行性价比评估是有必要的，特别是对于资源有限的人群。
